Literature DB >> 1906593

In vivo regulation of S. japonica granuloma formation by an IL-2 antagonist.

T F Kresina1.   

Abstract

The present study shows an in vivo role for interleukin-2 in the formation of hepatic granulomatous inflammation in murine Schistosoma japonicum infection. Mice which had been administered an inhibitor to interleukin-2 function during acute infection were noted to have reduced cell-mediated immune responses to ConA and S. japonicum soluble egg antigen (SEA). Lymphoid tissue from these treated mice also have reduced numbers of cells which could be activated by ConA to produce interleukin-2 mRNA as shown by in situ hybridization studies. Mice with less activated lymphocytes had, on the average, a 70% reduction in the granulomatous inflammation surrounding eggs deposited in hepatic tissues of acutely infected mice. The data demonstrate that IL-2 is a key factor in the generation of granulomatous inflammation in S. japonicum infection and suggest that a potential anti-pathology vaccine could be generated based on limiting the presence of IL-2 generated during acute infection.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1906593     DOI: 10.1017/s0031182000062557

Source DB:  PubMed          Journal:  Parasitology        ISSN: 0031-1820            Impact factor:   3.234


  2 in total

1.  Murine hepatocytes DNA changes as an assessment of the immunogenicity of potential anti-schistosomal vaccines experimentally.

Authors:  Samia E Etewa; Mohamed H A Hegab; Ashraf S Metwally; Somia H Abd Allah; Sally M Shalaby; Amal S El-Shal; Mohamed Baredy; Mahmoud A El Shafey; Howayda S F Moawad
Journal:  J Parasit Dis       Date:  2016-06-20

2.  Schistosoma japonicum-infected mice show reduced hepatic fibrosis and eosinophilia and selective inhibition of interleukin-5 secretion by CD4+ cells after treatment with anti-interleukin-2 antibodies.

Authors:  A W Cheever; Y Xu; A Sher; F D Finkelman; T M Cox; J G Macedonia
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.